Call for Abstracts

Overall Instructions for Abstracts

• Abstracts may not contain data that have been previously presented or will be presented or published prior to the 2024 Annual Meeting.
• All abstracts for the 2024 Annual Meeting must be submitted through our online submission portal.
• Institutional names are not to be included anywhere in the title or body of the abstract.
• Case reports will not be accepted.
• Word limit – 500 words or less. Word limit does not include title or authors. Abstracts that exceed the word limit will not be accepted.
• Abstracts submitted may include 1 table OR 1 figure. Abstracts submitted with more than 1 table or 1 figure will not be accepted.
• All words must be those of the authors. Abstracts written by artificial intelligence (AI) will not be accepted.
• Disclosure Declaration: The ASBrS disclosure policy promotes balance, independence, objectivity, and scientific rigor in all of its educational activities through the disclosure of financial or non-financial/strategic business relationships or partnerships (relationships) and mitigation of relevant relationships. The relationships requiring disclosure are outlined in the ASBrS CME Activity Disclosure Policy. All authors are required to disclose all financial, and non-financial/strategic, business relationships or partnerships (relationships) with any ineligible company they have had over the past 24 months.
• • Ineligible Company: “A for‐profit entity that develops, produces, markets, or distributes drugs, devices, services or therapies used to diagnose, treat, monitor, manage, and alleviate health conditions. This definition is not intended to include non‐profit entities, entities outside of the healthcare sector, or entities through which physicians provide clinical services directly to patients.”
  • If the first presenting author is employed by an ineligible company as defined by the ACCME, an alternate presenter who does not have a relevant employment relationship must be named if the abstract is selected for presentation in an oral abstract session. Oral abstract presenters will also be subject to the same disclosure review and management strategies as faculty. The alternate presenter should not be financially motivated or interested in presenting the abstract.
  • Oral abstract presenters will also be subject to the disclosure review and mitigation process outlined in the 'CME Activity Disclosure Process for Financial or Non-financial/Strategic Business Relationships or Partnerships'.
  • • Oral abstract presenters must disclose all financial, and non-financial/strategic, business relationships or partnerships (relationships) with any ineligible company they have had over the past 24 months.
    • Financial relationships of any dollar amount or non-financial/strategic business relationships or partnerships are defined as relevant if the educational content is related to the business lines or products of the ineligible company.
    • Should it be determined that a relevant relationship exists, the individual will be contacted by a designated ASBrS official with methods to mitigate the relationship.
    • An advanced conflict mitigation process will be initiated if the designated ASBrS official determines a relevant relationship requires additional review. The CME committee will determine the applicable parties for additional review.
    • If the relevant relationship cannot be mitigated, an alternate presenter must be named and will be subject to the 'CME Activity Disclosure Process for Financial or Non-financial/Strategic Business Relationships or Partnerships'.
    • All relevant relationships must be mitigated before the start of the annual meeting.
• All abstract submissions are subject to a non-refundable $60 submission fee.

Current Accruing Prospective Clinical Trials Abstracts

• Abstracts submitted in this category should describe the primary and secondary objectives of the trials, targeted accrual, sites the trial is open at, date of activation, anticipated study length, and trial design.
• Abstracts submitted to this category will be considered for poster presentation only.

Late Breaking Abstracts

• The ASBrS will accept late breaking abstracts specific to ONLY prospective clinical trials FOR WHICH PATIENTS SIGNED INFORMED CONSENT PRIOR TO PARTICIPATION.
• Abstracts that concern other data types will not be considered.
• To qualify as a late breaking abstract, submit a placeholder abstract by the general abstract deadline of November 8, 2023. The placeholder abstract should include background, methods and details of the clinical trial sample size, and potential implications of trial findings.
• The final version of the abstract is due on February 5, 2024. The final version of the late breaking abstract must include the final results.
• These abstracts will be considered by the Publications Committee for presentation, and those accepted will be notified.

Presentation Types

All abstracts will be reviewed by the ASBrS Publications Committee. Presentation dates are tentative and subject to change. The top abstracts will be selected for presentation in 1 of the following presentation formats:

• Oral: Oral presentations will be given during the Scientific Session on Friday, April 12, and Saturday, April 13, 2024. Each presenter will be given 6 minutes for their presentation, followed by 2-3 minutes for questions. (To be eligible for acceptance, you must have an author who will be available to present during the assigned session.)
• Quick Shot:Quick Shot presentations will be given on Saturday, April 13, 2024. Each presenter will be given 3 minutes for their presentation, which will be followed by a 2-minute discussion period. (To be eligible for acceptance, you must have an author who will be available to present during this session.)
• Poster: The Scientific Poster Session and Reception will be held on Friday, April 12, 2024. Your abstract’s presenter must be available to discuss the poster with interested meeting attendees during this session. ASBrS will provide thumbtacks and an 8-foot-wide by 4-foot-high carpeted, framed board on which to mount your poster.

Opportunities for Publication

• Accepted abstracts will be published online in Annals of Surgical Oncology.
• Authors of abstracts accepted for Oral and Quick Shot presentations and selected poster presentations are invited to submit a manuscript for possible publication in the October issue of Annals of Surgical Oncology. All manuscripts must be submitted by April 3, 2024. No extensions will be given for this deadline.
• Fellows, residents, and medical trainees presenting an Oral or Quick Shot presentation are required to submit a manuscript for possible publication in the October issue of Annals of Surgical Oncology in order to be considered for the George Peters Award or Scientific Presentation Award. All manuscripts must be submitted by April 3, 2024. No extensions will be given for this deadline. If a manuscript is not submitted, fellows, residents, and medical trainees will not be eligible for either of these awards.

Special Awards for Breast Fellows and Residents

Oral and Quick Shot presentations by a breast fellow will be considered for the following:

• The George Peters Award for the best abstract presented by a breast fellow. (Fellows eligible for this award are required to submit a manuscript to Annals of Surgical Oncology by April 3, 2024.) The award was established by the Society to honor Dr. George N. Peters, who was instrumental in bringing together the Susan G. Komen Breast Cancer Foundation, The American Society of Breast Surgeons, the American Society of Breast Disease, and the Society of Surgical Oncology to develop educational objectives for breast fellowships. The educational objectives were first used to award Komen Interdisciplinary Breast Fellowships. Subsequently, the curriculum was used for the breast fellowship credentialing process that has led to the development of a nationwide matching program for breast fellowships.

Oral and Quick Shot presentations by a trainee will be considered for the following:

• The Scientific Presentation Award for the best paper presented by a medical student, resident, or fellow. (Medical students, residents, or fellows eligible for this award are required to submit a manuscript to Annals of Surgical Oncology by April 3, 2024.)

A prize of $1,000 will be granted to the winner of the George Peters Award and $500 to the winner of the Scientific Presentation Award—both of which are supported by The American Society of Breast Surgeons Foundation.

All Oral presentations will be considered for the following:

• The Scientific Impact Award for the best paper as voted on by the audience. The winner of the Scientific Impact Award receives a plaque.

CME Clinical Content Validation